| Literature DB >> 34305216 |
Rohitash Yadav1, Shazia Hasan1, Sumit Mahato1, Ismail Celik2, Y S Mary3, Ashish Kumar4, Puneet Dhamija1, Ambika Sharma5, Neha Choudhary6, Pankaj Kumar Chaudhary7, Ankita Singh Kushwah7, Jitendra Kumar Chaudhary8.
Abstract
The scientific community is continuously working to discover drug candidates against potential targets of <span class="Species">SARS-CoV-2, but effective treatment has not been discovered yet. The virus enters the host cell through molecular interaction with its enzymatic receptors i.e., <ass="Chemical">span class="Gene">ACE2 and TMPRSS2, which, if, synergistically blocked can lead to the development of novel drug candidates. In this study, 1503 natural bioactive compounds were screened by HTVS, followed by SP and XP docking using Schrodinger Maestro software. Bio-0357 (protozide) and Bio-597 (chrysin) were selected for dynamics simulation based on synergistic binding affinity on S1 (docking score -9.642 and -8.78 kcal/mol) and S2 domains (-5.83 and -5.3 kcal/mol), and the RMSD, RMSF and Rg analyses showed stable interaction. The DFT analysis showed that the adsorption of protozide/chrysin, the band gap of protozide/chrysin-F/G reduced significantly. From SERS, results, it can be concluded that QDs nanocluster will act as a sensor for the detection of drugs. The docking study showed Bio-0357 and Bio-0597 bind to both S1 and S2 domains through stable molecular interactions, which can lead to the discovery of new drug candidates to prevent the entry of SARS-CoV-2. This in-silico study may be helpful to researchers for further in vitro experimental validation and development of new therapy for COVID-19.Entities:
Keywords: DFT; Dual inhibitor; MD simulations; SARS-CoV-2; Spike protein
Year: 2021 PMID: 34305216 PMCID: PMC8267125 DOI: 10.1016/j.molliq.2021.116942
Source DB: PubMed Journal: J Mol Liq ISSN: 0167-7322 Impact factor: 6.165
Fig. 1Virtual screening and docking workflow. HTVS (High throughput virtual screening); SP (Standard precision); XP (Extra precision); MDS (Molecular dynamics simulation).
Three dimensional structures of spike protein, ACE2 & TMPRSS2, and their properties.
| Protein structure | PDB ID | Method | Resolution | Sequence length | Number of chains |
|---|---|---|---|---|---|
| Spike glycoprotein | 6XR8 | Electron Microscope | 2.90 Å | 1310 | A,B,C |
| ACE2 | 6M0J | X-RAY DIFFRACTION | 2.45 Å | 603 | A |
Fig. 2Optimized structures of (a) fullerene (b) graphene (c) chrysin (d) protozide.
Dscore, size and active site residues of 6xr8 predicted by Schrodinger’s sitemap tools.
| S/N | Active Site | DScore | Residues |
|---|---|---|---|
| 1 | Site-1 | 1.00 | Leu18, Ala243, Leu244, Ser254, Ser255, Gly257, Trp258, Thr259, Ala260, Gly261, Ala262, I Le68, Hie69, Ly597, Ser98, Asn99, Ile100, Phe140, Val143, Tyr144, Tyr145, Trp152, Glu156, Arg158, Leu179, Gly181, Lys182, Gln183, Gly184 |
| 2 | Site-2 | 1.09 | Val729, Ser730, Met731, Thr732, Lys733, Gln774, Asp775, Thr778, Phe782, Phe823, Ala831, Gly832, Phe833, Leu861, Pro862, Pro863, Leu864, Leu865, Thr866, Asp867, Ile870, Ser1055, Ala1056, Pro1057, Hie1058, Gly1059 |
| 3 | Site-3 | 1.468 | Cys336, Pro337, Phe338, Val341, Phe342, Ile358, Ala363, Tyr365, Leu368, Tyr369, Ala372, Phe374, Phe377, Leu387, Phe392, Val395, Cys432, Ile434, Leu513, Phe515, Val524. |
| 4 | Site-4 | 0.9 | 94, 96, 99, 101, 102, 103, 104, 119, 121, 126, 128, 177, 190, 192, 194, 203, 226, 227 |
| 5 | Site-5 | 0.8 | 907, 910, 911, 912, 914, 1091, 1092, 1093, 1104, 1105, 1106, 1107, 1108, 1111, 1113, 1119 |
Docking Results of Bioactive Phyto-compounds Compounds from ibscreen database against site 1, 2 & 3 1.46 of 6XR8 target protein.
| Site-3 (DScore 1.46) | Site-2 (DScore 1.09) | Site-1 (DScore 1.00) | ||||
|---|---|---|---|---|---|---|
| S/No | Compound ID | Docking Score | Compound ID | Docking Score | Compound ID | Docking Score |
| 1 | Bio-0675 | −10.38 | Bio-0174 | −6.73 | Bio-0613 | −6.85 |
| 2 | Bio-0677 | −9.85 | Bio-0043 | −6.53 | Bio-0109 | −6.34 |
| 3 | Bio-0357 | −9.642 | Bio-0287 | −6.42 | Bio-0312 | −6.18 |
| 4 | Bio-0625 | −9.592 | Bio-0924 | −5.96 | Bio-0034 | −6.12 |
| 5 | Bio-0002 | −9.577 | Bio-0597 | −5.83 | Bio-0219 | −6.02 |
| 6 | Bio-0437 | −9.153 | Bio-0617 | −5.63 | Bio-0247 | −5.79 |
| 7 | Bio-0597 | −8.78 | Bio-0640 | −5.45 | Bio-0047 | −5.78 |
| 8 | Bio-0224 | −8.678 | Bio-0357 | −5.30 | Bio-0594 | −5.76 |
| 9 | Bio-0385 | −8.649 | Bio-0369 | −5.19 | Bio-0444 | −5.71 |
| 10 | Bio-0004 | −8.632 | Bio-0808 | −5.18 | Bio-0357 | −5.69 |
Fig. 3Physiochemical interactions of protein–protein docking complex. A) protein–protein. Docking interactive residues between spike protein and ACE2. B) Protein-protein docking interactive residues between spike protein and ACE2 with TMPRSS2.
Fig. 4(a) Root Mean Square Deviation (RMSD) of ligand protein complex of Bio-0357, Bio-597 and apo form for 50 ns. (b) Root Mean Square Fluctuation (RMSF) of ligand protein complex of Bio-0357, Bio-597 and apo form for 50 ns. (c)Radius of gyration (Rg) shows the ligand–protein complex of Bio-0357, Bio-597 and apo form for 50 ns. (d) The number of Intermolecular H bonds between the ligands (Bio-375 & Bio-597) and amino acid residues of SARS CoV-2 spike glycoprotein (pdb id: 6xr8) during 50 ns.
Fig. 5Optimized structures of (a) protozide-F (b) protozide-G (c) chrysin-F (d) chrysin-G.
Fig. 6HOMO-LUMO plots of (a) protozide (b) protozide-F (c) protozide-G (d) chrysin (e) chrysin-F (f) chrysin-G.
Fig. 7MEP plots of (a) protozide (b) protozide-F (c) protozide-G (d) chrysin (e) chrysin-F (f) chrysin-G.